Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols FHL2 and SPRY4	Name 1 four and a half LIM domains 2	Name2 sprouty RTK signaling antagonist 4	Pathway 1 PPARA activates gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CCN3 and TNIP3	Name 1 cellular communication network factor 3	Name2 TNFAIP3 interacting protein 3	Pathway 1	Pathway 2 Ovarian tumor domain proteases	Drugs 1 Insulin human	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols AFDN and NRXN1	Name 1 afadin, adherens junction formation factor	Name2 neurexin 1	Pathway 1	Pathway 2 Neurexins and neuroligins Neurexins and neuroligins Non-integrin membrane-ECM interactions Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one	Drugs 2 Calcium citrate Calcium Phosphate Calcium phosphate dihydrate	Diseases 1	Diseases 2 Pitt-Hopkins syndrome, including: Pitt-Hopkins syndrome; Pitt-Hopkins-like syndrome
Novel Novel	Symbols AFDN and NRXN3	Name 1 afadin, adherens junction formation factor	Name2 neurexin 3	Pathway 1	Pathway 2 Neurexins and neuroligins Neurexins and neuroligins Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols NEB and TMOD1	Name 1 nebulin	Name2 tropomodulin 1	Pathway 1 Striated Muscle Contraction	Pathway 2 Striated Muscle Contraction	Drugs 1	Drugs 2	Diseases 1 Distal muscular dystrophies, including: Welander distal myopathy (WDM); Tibial muscular dystrophy (TMD); Nonaka distal myopathy with rimmed vacuoles (DMRV); Miyoshi myopathy (MM); Laing myopathy (MPD1); Distal nebulin myopathy (DNM); Distal desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Distal myotilinopathy (MFM3); Distal zaspopathy (MFM4); Distal myopathy 3 (MPD2, VCPDM) Nemaline myopathy	Diseases 2
Novel Novel	Symbols NGFR and PRKACB	Name 1 nerve growth factor receptor	Name2 protein kinase cAMP-activated catalytic subunit beta	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 PKA-mediated phosphorylation of CREB PKA-mediated phosphorylation of key metabolic factors Triglyceride catabolism PKA activation PKA activation in glucagon signalling DARPP-32 events Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Rap1 signalling Regulation of insulin secretion Vasopressin regulates renal water homeostasis via Aquaporins VEGFA-VEGFR2 Pathway CREB1 phosphorylation through the activation of Adenylate Cyclase CREB1 phosphorylation through the activation of Adenylate Cyclase Degradation of GLI1 by the proteasome Degradation of GLI2 by the proteasome GLI3 is processed to GLI3R by the proteasome Hedgehog 'off' state CD209 (DC-SIGN) signaling MAPK6/MAPK4 signaling RET signaling HDL assembly ROBO receptors bind AKAP5 GPER1 signaling GPER1 signaling Regulation of glycolysis by fructose 2,6-bisphosphate metabolism ADORA2B mediated anti-inflammatory cytokines production ADORA2B mediated anti-inflammatory cytokines production FCGR3A-mediated IL10 synthesis FCGR3A-mediated IL10 synthesis Factors involved in megakaryocyte development and platelet production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1	Drugs 2 Phosphonothreonine Fostamatinib	Diseases 1	Diseases 2
Novel Novel	Symbols NGFR and NTRK2	Name 1 nerve growth factor receptor	Name2 neurotrophic receptor tyrosine kinase 2	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 PIP3 activates AKT signaling NGF-independant TRKA activation Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling BDNF activates NTRK2 (TRKB) signaling NTF3 activates NTRK2 (TRKB) signaling NTF4 activates NTRK2 (TRKB) signaling Activated NTRK2 signals through RAS Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PI3K Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FYN NTRK2 activates RAC1 NTRK2 activates RAC1 Activated NTRK2 signals through CDK5	Drugs 1	Drugs 2 Amitriptyline Esketamine Entrectinib Fostamatinib Larotrectinib	Diseases 1	Diseases 2 Neuroblastoma
Novel Novel	Symbols NGFR and ZNF274	Name 1 nerve growth factor receptor	Name2 zinc finger protein 274	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 Generic Transcription Pathway	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols NGFR and NTF4	Name 1 nerve growth factor receptor	Name2 neurotrophin 4	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling NTF4 activates NTRK2 (TRKB) signaling Activated NTRK2 signals through RAS Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PI3K Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Primary open angle glaucoma
Novel Novel	Symbols NPY1R and LSM7	Name 1 neuropeptide Y receptor Y1	Name2 LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated	Pathway 1 Peptide ligand-binding receptors G alpha (i) signalling events	Pathway 2 mRNA decay by 5' to 3' exoribonuclease mRNA decay by 5' to 3' exoribonuclease mRNA Splicing - Major Pathway	Drugs 1 Peptide YY (3-36)	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols SNCA and SNCAIP	Name 1 synuclein alpha	Name2 synuclein alpha interacting protein	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Amyloid fiber formation	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and ZRANB1	Name 1 synuclein alpha	Name2 zinc finger RANBP2-type containing 1	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Degradation of beta-catenin by the destruction complex Ovarian tumor domain proteases	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and BASP1	Name 1 synuclein alpha	Name2 brain abundant membrane attached signal protein 1	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 RHOF GTPase cycle	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and ACTR1A	Name 1 synuclein alpha	Name2 actin related protein 1A	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 MHC class II antigen presentation Regulation of PLK1 Activity at G2/M Transition HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic AURKA Activation by TPX2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and ARAP3	Name 1 synuclein alpha	Name2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC3 GTPase cycle	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and BET1	Name 1 synuclein alpha	Name2 Bet1 golgi vesicular membrane trafficking protein	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 COPII-mediated vesicle transport COPI-mediated anterograde transport	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and CLSTN2	Name 1 synuclein alpha	Name2 calsyntenin 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and DNM3	Name 1 synuclein alpha	Name2 dynamin 3	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Toll Like Receptor 4 (TLR4) Cascade Retrograde neurotrophin signalling MHC class II antigen presentation Recycling pathway of L1 Clathrin-mediated endocytosis	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and AGO2	Name 1 synuclein alpha	Name2 argonaute RISC catalytic component 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Pre-NOTCH Transcription and Translation MicroRNA (miRNA) biogenesis Ca2+ pathway Small interfering RNA (siRNA) biogenesis Post-transcriptional silencing by small RNAs Transcriptional regulation by small RNAs TP53 Regulates Metabolic Genes MAPK6/MAPK4 signaling Regulation of RUNX1 Expression and Activity Regulation of PTEN mRNA translation Competing endogenous RNAs (ceRNAs) regulate PTEN translation Transcriptional Regulation by MECP2 Transcriptional Regulation by MECP2 Estrogen-dependent gene expression Regulation of MECP2 expression and activity NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux Nuclear events stimulated by ALK signaling in cancer Regulation of CDH11 mRNA translation by microRNAs Regulation of CDH11 mRNA translation by microRNAs Regulation of CDH1 mRNA translation by microRNAs Regulation of NPAS4 mRNA translation M-decay: degradation of maternal mRNAs by maternally stored factors Regulation of MITF-M-dependent genes involved in apoptosis TGFBR3 expression Regulation of PD-L1(CD274) translation	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel Novel	Symbols SNCA and EXOC1	Name 1 synuclein alpha	Name2 exocyst complex component 1	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Translocation of SLC2A4 (GLUT4) to the plasma membrane Insulin processing VxPx cargo-targeting to cilium	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols FHL2 and SPRY4	Name 1 four and a half LIM domains 2	Name2 sprouty RTK signaling antagonist 4	Pathway 1 PPARA activates gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CCN3 and TNIP3	Name 1 cellular communication network factor 3	Name2 TNFAIP3 interacting protein 3	Pathway 1	Pathway 2 Ovarian tumor domain proteases	Drugs 1 Insulin human	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols AFDN and NRXN1	Name 1 afadin, adherens junction formation factor	Name2 neurexin 1	Pathway 1	Pathway 2 Neurexins and neuroligins Neurexins and neuroligins Non-integrin membrane-ECM interactions Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one	Drugs 2 Calcium citrate Calcium Phosphate Calcium phosphate dihydrate	Diseases 1	Diseases 2 Pitt-Hopkins syndrome, including: Pitt-Hopkins syndrome; Pitt-Hopkins-like syndrome
Novel	Symbols AFDN and NRXN3	Name 1 afadin, adherens junction formation factor	Name2 neurexin 3	Pathway 1	Pathway 2 Neurexins and neuroligins Neurexins and neuroligins Neurexins and neuroligins Neurexins and neuroligins	Drugs 1 (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols NEB and TMOD1	Name 1 nebulin	Name2 tropomodulin 1	Pathway 1 Striated Muscle Contraction	Pathway 2 Striated Muscle Contraction	Drugs 1	Drugs 2	Diseases 1 Distal muscular dystrophies, including: Welander distal myopathy (WDM); Tibial muscular dystrophy (TMD); Nonaka distal myopathy with rimmed vacuoles (DMRV); Miyoshi myopathy (MM); Laing myopathy (MPD1); Distal nebulin myopathy (DNM); Distal desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Distal myotilinopathy (MFM3); Distal zaspopathy (MFM4); Distal myopathy 3 (MPD2, VCPDM) Nemaline myopathy	Diseases 2
Novel	Symbols NGFR and PRKACB	Name 1 nerve growth factor receptor	Name2 protein kinase cAMP-activated catalytic subunit beta	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 PKA-mediated phosphorylation of CREB PKA-mediated phosphorylation of key metabolic factors Triglyceride catabolism PKA activation PKA activation in glucagon signalling DARPP-32 events Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Rap1 signalling Regulation of insulin secretion Vasopressin regulates renal water homeostasis via Aquaporins VEGFA-VEGFR2 Pathway CREB1 phosphorylation through the activation of Adenylate Cyclase CREB1 phosphorylation through the activation of Adenylate Cyclase Degradation of GLI1 by the proteasome Degradation of GLI2 by the proteasome GLI3 is processed to GLI3R by the proteasome Hedgehog 'off' state CD209 (DC-SIGN) signaling MAPK6/MAPK4 signaling RET signaling HDL assembly ROBO receptors bind AKAP5 GPER1 signaling GPER1 signaling Regulation of glycolysis by fructose 2,6-bisphosphate metabolism ADORA2B mediated anti-inflammatory cytokines production ADORA2B mediated anti-inflammatory cytokines production FCGR3A-mediated IL10 synthesis FCGR3A-mediated IL10 synthesis Factors involved in megakaryocyte development and platelet production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Drugs 1	Drugs 2 Phosphonothreonine Fostamatinib	Diseases 1	Diseases 2
Novel	Symbols NGFR and NTRK2	Name 1 nerve growth factor receptor	Name2 neurotrophic receptor tyrosine kinase 2	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 PIP3 activates AKT signaling NGF-independant TRKA activation Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling BDNF activates NTRK2 (TRKB) signaling NTF3 activates NTRK2 (TRKB) signaling NTF4 activates NTRK2 (TRKB) signaling Activated NTRK2 signals through RAS Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PI3K Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FYN NTRK2 activates RAC1 NTRK2 activates RAC1 Activated NTRK2 signals through CDK5	Drugs 1	Drugs 2 Amitriptyline Esketamine Entrectinib Fostamatinib Larotrectinib	Diseases 1	Diseases 2 Neuroblastoma
Novel	Symbols NGFR and ZNF274	Name 1 nerve growth factor receptor	Name2 zinc finger protein 274	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 Generic Transcription Pathway	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols NGFR and NTF4	Name 1 nerve growth factor receptor	Name2 neurotrophin 4	Pathway 1 Axonal growth inhibition (RHOA activation) NRAGE signals death through JNK p75NTR negatively regulates cell cycle via SC1 Ceramide signalling Regulated proteolysis of p75NTR NFG and proNGF binds to p75NTR NADE modulates death signalling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival Axonal growth stimulation	Pathway 2 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling NTF4 activates NTRK2 (TRKB) signaling Activated NTRK2 signals through RAS Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PI3K Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Primary open angle glaucoma
Novel	Symbols NPY1R and LSM7	Name 1 neuropeptide Y receptor Y1	Name2 LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated	Pathway 1 Peptide ligand-binding receptors G alpha (i) signalling events	Pathway 2 mRNA decay by 5' to 3' exoribonuclease mRNA decay by 5' to 3' exoribonuclease mRNA Splicing - Major Pathway	Drugs 1 Peptide YY (3-36)	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols SNCA and SNCAIP	Name 1 synuclein alpha	Name2 synuclein alpha interacting protein	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Amyloid fiber formation	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and ZRANB1	Name 1 synuclein alpha	Name2 zinc finger RANBP2-type containing 1	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Degradation of beta-catenin by the destruction complex Ovarian tumor domain proteases	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and BASP1	Name 1 synuclein alpha	Name2 brain abundant membrane attached signal protein 1	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 RHOF GTPase cycle	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and ACTR1A	Name 1 synuclein alpha	Name2 actin related protein 1A	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 MHC class II antigen presentation Regulation of PLK1 Activity at G2/M Transition HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic AURKA Activation by TPX2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and ARAP3	Name 1 synuclein alpha	Name2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC3 GTPase cycle	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and BET1	Name 1 synuclein alpha	Name2 Bet1 golgi vesicular membrane trafficking protein	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 COPII-mediated vesicle transport COPI-mediated anterograde transport	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and CLSTN2	Name 1 synuclein alpha	Name2 calsyntenin 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and DNM3	Name 1 synuclein alpha	Name2 dynamin 3	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Toll Like Receptor 4 (TLR4) Cascade Retrograde neurotrophin signalling MHC class II antigen presentation Recycling pathway of L1 Clathrin-mediated endocytosis	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and AGO2	Name 1 synuclein alpha	Name2 argonaute RISC catalytic component 2	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Pre-NOTCH Transcription and Translation MicroRNA (miRNA) biogenesis Ca2+ pathway Small interfering RNA (siRNA) biogenesis Post-transcriptional silencing by small RNAs Transcriptional regulation by small RNAs TP53 Regulates Metabolic Genes MAPK6/MAPK4 signaling Regulation of RUNX1 Expression and Activity Regulation of PTEN mRNA translation Competing endogenous RNAs (ceRNAs) regulate PTEN translation Transcriptional Regulation by MECP2 Transcriptional Regulation by MECP2 Estrogen-dependent gene expression Regulation of MECP2 expression and activity NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux Nuclear events stimulated by ALK signaling in cancer Regulation of CDH11 mRNA translation by microRNAs Regulation of CDH11 mRNA translation by microRNAs Regulation of CDH1 mRNA translation by microRNAs Regulation of NPAS4 mRNA translation M-decay: degradation of maternal mRNAs by maternally stored factors Regulation of MITF-M-dependent genes involved in apoptosis TGFBR3 expression Regulation of PD-L1(CD274) translation	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2
Novel	Symbols SNCA and EXOC1	Name 1 synuclein alpha	Name2 exocyst complex component 1	Pathway 1 Amyloid fiber formation PKR-mediated signaling	Pathway 2 Translocation of SLC2A4 (GLUT4) to the plasma membrane Insulin processing VxPx cargo-targeting to cilium	Drugs 1 Resveratrol Dequalinium Copper	Drugs 2	Diseases 1 Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)	Diseases 2

Page 40 out of 98 pages

Search Results : Cancer